Cardio3 Biosciences SA
This article was originally published in Start Up
Executive Summary
In March 2009, Belgium's Cardio3 BioSciences announced that a patient with chronic heart failure had for the first time received its C-Cure, a stem cell-based therapy developed to help heal damaged heart tissue. The procedure involved transplantation of the patient's own bone-marrow cells, which had been cultured and implanted according to specialized protocols. The company claims it has proved that its cells become cardiac myocytes, and are also part of the new vessels that are generated post-therapy. The Cardio3's scientists could also demonstrate that the implanted cells did not cause arrhythmia and thus were electrically linked to the rest of the tissue in the heart.
You may also be interested in...
CellDesign Inc.
Current cellular models for drug discovery can be notoriously unreliable, both for their predictive power and their sustainability. Cells derived from human progenitor stem cells can provide homogeneity over countless experiments, but working with them remains a complex scientific art. By industrializing production of stem cell-derived cell model systems, CellDesign Inc. intends to capture a chunk of the existing $1.5 billion market for cellular model systems and grow it through sales of easy-to-use kits for deriving everything from human fat cells to Alzheimer's disease-ridden neurons.
Fate Therapeutics Inc.
While some stem cell companies strive to develop neatly packaged products for specific medical niches, and some aim to supply research tools others will use, Fate Therapeutics is planning to do all that and more. The La Jolla, CA-based start-up founded in November 2007 has recruited an all-star team of scientists, clinicians, executives, and investors who together are pursuing the ultimate prize-the ability to restore health to diseased or damaged cells, and to find new therapeutics for many kinds of conditions that currently have limited or no treatment options.
Amorcyte Inc.
Amorcyte is intent on developing patients' own enriched bone-marrow stem cells as a treatment for cardiovascular disease. The idea is to infuse the stem cells into the heart a week or so after a severe heart attack, where they will linger and help restore damaged tissue. Results of a Phase I clinical trial recently reported at the scientific session of the American College of Cardiology conference showed the treatment was safe, and yielded insight into the minimum dosage necessary to generate a beneficial effect.